ObsEva - OBSV Stock Forecast, Price & News

ObsEva SA, a biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for women suffering from reproductive health and pregnancy. It is developing Linzagolix, an oral gonadotropin releasing hormone receptor antagonist that is in Phase III clinical trial for the treatment of pain associated with endometriosis and heavy menstrual bleeding associated with uterine fibroids in pre-menopausal women. The company is also involved in developing Ebopiprant, an oral and selective prostaglandin F2a, or PGF2a receptor antagonist, which is in Phase II clinical trial as a once daily treatment for preterm labor in weeks 24 to 34 of gestational age; and Nolasiban, an oral oxytocin receptor antagonist that is in Phase I clinical trial to enhance clinical pregnancy and live birth rates in women undergoing in vitro fertilization. ObsEva SA was founded in 2012 and is headquartered in Geneva, Switzerland.

ObsEva Stock Performance

Shares of NASDAQ:OBSV opened at $0.26 on Wednesday. The company has a market capitalization of $20.58 million, a P/E ratio of -0.41 and a beta of 0.21. The business's 50-day moving average price is $1.31 and its two-hundred day moving average price is $1.41. ObsEva has a one year low of $0.22 and a one year high of $3.35. The company has a debt-to-equity ratio of 1.18, a current ratio of 3.09 and a quick ratio of 3.09.

ObsEva (NASDAQ:OBSV - Get Rating) last released its quarterly earnings results on Tuesday, May 17th. The company reported ($0.14) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.25) by $0.11. The company had revenue of $2.24 million for the quarter. Analysts anticipate that ObsEva will post -0.75 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of research analysts have issued reports on the company. StockNews.com assumed coverage on ObsEva in a research report on Saturday. They set a "hold" rating for the company. Canaccord Genuity Group downgraded ObsEva from a "buy" rating to a "hold" rating and dropped their price objective for the stock from $12.00 to $1.00 in a research note on Monday, August 1st. Canaccord Genuity Group assumed coverage on ObsEva in a research note on Tuesday, April 26th. They issued a "buy" rating and a $12.00 price objective on the stock. Cantor Fitzgerald lowered ObsEva from an "overweight" rating to a "neutral" rating in a research report on Thursday, July 28th. Finally, HC Wainwright reaffirmed a "buy" rating and set a $11.00 target price on shares of ObsEva in a research report on Tuesday, June 21st. Three analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. According to data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $10.50.